Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: Findings from the zoster quality of life (ZQOL) study

Health and Quality of Life Outcomes

Volumn 12, Issue 1, 2014, Pages

  Serpell, Mick ^a   Gater, Adam ^b   Carroll, Stuart ^c   Abetz Webb, Linda ^b   Mannan, Azharul ^c   Johnson, Robert ^d  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b ADELPHI REAL WORLD   (United Kingdom)

^c Sanofi Pasteur MSD   (United Kingdom)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; AGED; ANALGESIA; ARTICLE; BRIEF PAIN INVENTORY; CONSULTATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HEALTH CARE PERSONNEL; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; QUESTIONNAIRE; SECONDARY CARE CENTER; SHORT FORM 36; TERTIARY CARE CENTER; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PAIN MEASUREMENT; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84902689006     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-12-92     Document Type: Article

References (62)

1. Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003, 70(Suppl 1):S9-14.
2. Schmader K, Gnann JW, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008, 197:S207-S215. 10.1086/522152, 18419399.
3. Pinchinat S, Cebrian-Cuenca A, Bricout H, Johnson R. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013, 13:170. 10.1186/1471-2334-13-170, 3637114, 23574765.
4. Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 2007, 7:1581-1595. 10.1586/14737175.7.11.1581, 17997705.
5. Dworkin RH, Schmader KE. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. Herpes zoster and postherpetic neuralgia 2001, 39-64. Amsterdam: Elsevier, 2.
6. Mick G, Hans G. Postherpetic neuralgia in Europe: the scale of the problem and outlook for the future. Journal of Clinical Gerontology and Geriatrics 2013, 4:102-108.
7. van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006, 35:132-137. 10.1093/ageing/afj048, 16431855.
8. Helgason S, Petursson G, Gudmundsson S, Sigurdsson JA. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000, 321:794. 10.1136/bmj.321.7264.794, 27491, 11009518.
9. Choo PW, Galil K, Donahue JG, Walker AM, Spiegelman D, Platt R. Risk factors for postherpetic neuralgia. Arch Intern Med 1997, 157:1217-1224. 10.1001/archinte.1997.00440320117011, 9183233.
10. Coen PG, Scott F, Leedham-Green M, Nia T, Jamil A, Johnson RW, Breuer J. Predicting and preventing post-herpetic neuralgia: are current risk factors useful in clinical practice?. Eur J Pain 2006, 10:695-700. 10.1016/j.ejpain.2005.11.002, 16427792.
11. Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Canadian Medical Association Journal 2010, 182:1731-1736. 10.1503/cmaj.091711, 2972323, 20921251.
12. Bowsher D. The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999, 3:335-342. 10.1016/S1090-3801(99)90015-0, 10700361.
13. Gauthier A, Breuer J, Carrington D, Martin M, Remy V. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2009, 137:38-47. 10.1017/S0950268808000678, 18466661.
14. Chidiac C, Bruxelle J, Daures J-P, Hoang-Xuan T, Morel P, Leplège A, El Hasnaoui A, de Labareyre C. Characteristics of Patients with Herpes Zoster on Presentation to Practitioners in France. Clinical Infectious Diseases 2001, 33:62-69. 10.1086/320884, 11389496.
15. Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. The journal of pain: official journal of the American Pain Society 2005, 6(6):356-363. 10.1016/j.jpain.2005.01.359, 15943957.
16. Brisson M, Pellissier JM, Camden S, Quach C, De WP. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia. Hum Vaccin 2008, 4:238-245. 10.4161/hv.4.3.5686, 18382137.
17. Cebrian-Cuenca AM, Diez-Domingo J, San-Martin-Rodriguez M, Puig-Barbera J, Navarro-Perez J. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. BMC Infect Dis 2011, 11:302. 10.1186/1471-2334-11-302, 3235981, 22044665.
18. Dworkin RH, White R, O'Connor AB, Baser O, Hawkins K. Healthcare costs of acute and chronic pain associated with a diagnosis of herpes zoster. J Am Geriatr Soc 2007, 55:1168-1175. 10.1111/j.1532-5415.2007.01231.x, 17661954.
19. Dworkin RH, Malone DC, Panarites CJ, Armstrong EP, Pham SV. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 2010, 11:360-368. 10.1016/j.jpain.2009.08.005, 19853529.
20. Rothberg MB, Virapongse A, Smith KJ. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Clin Infect Dis 2007, 44:1280-1288. 10.1086/514342, 17443464.
21. Ultsch B, Koster I, Reinhold T, Siedler A, Krause G, Icks A, Schubert I, Wichmann O. Epidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. Eur J Health Econ 2013, 14(6):1015-1026. 10.1007/s10198-012-0452-1, 23271349.
22. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of herpes zoster: a prospective population based study. Vaccine 2006, 24:1308-1314. 10.1016/j.vaccine.2005.09.026, 16352376.
23. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:800-802.
24. Lancaster T, Silagy C, Gray S. Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials. Br J Gen Pract 1995, 45:39-45. 1239112, 7779475.
25. Volpi A, Gatti A, Serafini G, Costa B, Suligoi B, Pica F, Marsella LT, Sabato E, Sabato AF. Clinical and psychosocial correlates of acute pain in herpes zoster. Journal of Clinical virology: the Official publication of the Pan American Society for Clinical Virology 2007, 38:275-279. 10.1016/j.jcv.2007.01.010, 17339131.
26. Coplan PM, Schmader K, Nikas A, Chan ISF, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory. The Journal of pain: Official Journal of the American Pain Society 2004, 5:344-356. 10.1016/j.jpain.2004.06.001, 15336639.
27. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ. Pain and Its Treatment in Outpatients with Metastatic Cancer. New England Journal of Medicine 1994, 330:592-596. 10.1056/NEJM199403033300902, 7508092.
28. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, Chan ISF, Choo P, Levin MJ, Johnson G, Williams HM, Oxman MN. The Impact of Acute Herpes Zoster Pain and Discomfort on Functional Status and Quality of Life in Older Adults. The Clinical Journal of Pain 2007, 23:490-496. 10.1097/AJP.0b013e318065b6c9, 17575488.
29. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. conceptual framework and item selection. Med Care 1992, 30:473-483. 10.1097/00005650-199206000-00002, 1593914.
30. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis 2004, 39:342-348. 10.1086/421942, 15307000.
31. Ware JE. SF-36 health survey update. Spine (Phila Pa 1976) 2000, 25:3130-3139. 10.1097/00007632-200012150-00008, 11124729.
32. Rabin R, de CF. EQ-5D: a measure of health status from the EuroQol group. Ann Med 2001, 33:337-343. 10.3109/07853890109002087, 11491192.
33. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes 2004, 2:12. 10.1186/1477-7525-2-12, 398419, 14987333.
34. World Medical Association Declaration of Helsinki (October 2008) 2008, http://www.wma.net/en/30publications/10policies/b3/17c.pdf (accessed 28th May 2012), World Medical Association.
35. Department of Health Research governance framework for health and social care 2005, http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4122427.pdf (Accessed 28th May 2012), Department of Health.
36. SF-36 v2 US population norms 1998, Lincoln: QualityMetric Incorporated.
37. Kind P, Hardman G, Macran S. UK population norms for EQ-5D 1999, York: Centre for Health Economics, University of York. Working Papers.
38. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, . Clinical Significance Consensus Meeting Group Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002, 77:371-383. 10.4065/77.4.371, 11936935, Clinical Significance Consensus Meeting Group.
39. Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: another step toward consensus. J Clin Epidemiol 2005, 58(12):1217-1219. 10.1016/j.jclinepi.2005.07.009, 16291464.
40. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999, 52(9):861-873. 10.1016/S0895-4356(99)00071-2, 10529027.
41. Hurley RW, Adams MCB. Sex, gender, and pain: an overview of a complex field. Anesthesia & Analgesia 2008, 107:309-317. 10.1213/01.ane.0b013e31816ba437, 2715547, 18635502.
42. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS. When is cancer pain mild, moderate or severe? grading pain severity by its interference with function. Pain 1995, 61:277-284. 10.1016/0304-3959(94)00178-H, 7659438.
43. World Health Organization Traitement de la douleur cancéreuse 1987, Geneva, Switzerland: World Health Organization, World Health Organization.
44. Cleeland C. Measurement of pain by subjective report. Advances in Pain Research and Therapy 1989, 12:391-403.
45. Gater A, Abetz-Webb L, Carroll S, Mannan A, Serpell M, Johnson RW. Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. 2014, in press.
46. Jung BF, Johnson RW, Griffin DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004, 62:1545-1551. 10.1212/01.WNL.0000123261.00004.29, 15136679.
47. Volpi A, Gatti A, Pica F, Bellino S, Marsella LT, Sabato AF. Clinical and psychosocial correlates of post-herpetic neuralgia. J Med Virol 2008, 80:1646-1652. 10.1002/jmv.21254, 18649332.
48. Pappagallo M, Oaklander AL, Quatrano-Piacentini AL, Clark MR, Raja SN. Heterogenous patterns of sensory dysfunction in postherpetic neuralgia suggest multiple pathophysiologic mechanisms. Anesthesiology 2000, 92:691-698. 10.1097/00000542-200003000-00013, 10719948.
49. Buonocore M, Gatti AM, Amato G, Aloisi AM, Bonezzi C. Allodynic skin in post-herpetic neuralgia: Histological correlates. Journal of Cellular Physiology 2012, 227:934-938. 10.1002/jcp.22804, 21503891.
50. Obidoa CA, Reisine SL, Cherniack M. How does the SF-36 perform in healthy populations? a structured review of longitudinal studies. Journal of Social, Behavioral, and Health Sciences 2010, 1.
51. Johnson RW, Griffiths P. Global strategies to prevent herpes zoster and its associated complications. Herpes 2007, 14(2):24.
52. Schmader K. Treatment and prevention strategies for herpes zoster and postherpetic neuralgia in older adults. Clin Geriatrics 2006, 14:26-33.
53. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, Betts RF, Gershon AA, Haanpää ML, McKendrick MW, Nurmikko TJ, Oaklander AL, Oxman MN, Langston DP, Petersen KL, Rowbotham MC, Schmader KE, Stacey BR, Tyring SK, Sijck AJMV, Wallace MS, Wassilew SW, Whitley RJ. Recommendations for the management of herpes zoster. Clinical Infectious Diseases 2007, 44:S1-26. 10.1086/510206, 17143845.
54. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995, 39:1546-1553. 10.1128/AAC.39.7.1546, 162779, 7492102.
55. Tyring SK, Beutner KR, Tucker BA, Anderson WC, Crooks RJ. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000, 9:863-869. 10.1001/archfami.9.9.863, 11031393.
56. Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009, 2:2.
57. Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2009, 2:2.
58. Oxman MN, Levin MJ. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis 2008, 197(Suppl 2):S228-S236. 4017882, 18419402.
59. Carroll S, Gater A, Abetz-Webb L, Smith F, Demuth D, Mannan A. Challenges in quantifying the patient-reported burden of herpes zoster and post-herpetic neuralgia in the UK: learnings from the zoster quality of life (ZQOL) study. BMC Res Notes 2013, 6:486. 10.1186/1756-0500-6-486, 24274819.
60. Dworkin RH. Racial differences in herpes zoster and age at onset of varicella. J Infect Dis 1996, 174:239-241. 10.1093/infdis/174.1.239, 8656005.
61. Schmader K, George LK, Burchett BM, Pieper CF, Hamilton JD. Racial differences in the occurrence of herpes zoster. J Infect Dis 1995, 171:701-704. 10.1093/infdis/171.3.701, 7876622.
62. Talukder YS, Kafatos G, Pinot de MOIRA A, Aquilina J, Parker SP, Crowcroft NS, Brown DWG, Breuer J. The seroepidemiology of varicella zoster virus among pregnant Bangladeshi and white British women in the London Borough of Tower Hamlets, UK. Epidemiology & Infection 2007, 135:1344-1353. 2870708, 17445317.